Analysis Article • Jun 05
Have your own idea? Try our Stock Screener
Polish (WIG) Clinical Research and Equipment Industry Analysis
UpdatedAug 05, 2026
DataAggregated Company Financials
Companies4
- 7D4.4%
- 3M-23.3%
- 1Y-33.0%
- YTDn/a
The Clinical Research and Equipment industry is up 4.4% in the last week, with Selvita up 8.7%. Meanwhile, Medicofarma Biotech actually underperformed within the industry, shrinking 6.0% in the last week. However, the industry is down 33% over the past year. Earnings are forecast to grow by 34% annually.
Industry Valuation and Performance
Has the Polish Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 06 Aug 2026 | zł995.6m | zł447.8m | -zł104,204,195.00 | n/a | -9.6x | 2.2x |
| Sat, 04 Jul 2026 | zł1.1b | zł448.4m | -zł104,204,195.00 | n/a | -10.2x | 2.4x |
| Mon, 01 Jun 2026 | zł1.1b | zł448.4m | -zł104,204,195.00 | n/a | -10.2x | 2.4x |
| Wed, 29 Apr 2026 | zł1.2b | zł459.0m | -zł102,646,524.00 | 774.4x | -11.8x | 2.6x |
| Fri, 27 Mar 2026 | zł1.2b | zł461.9m | -zł107,178,157.00 | n/a | -11.1x | 2.6x |
| Sun, 22 Feb 2026 | zł1.4b | zł464.6m | -zł124,641,157.00 | n/a | -11.3x | 3x |
| Tue, 20 Jan 2026 | zł1.5b | zł464.6m | -zł124,641,157.00 | n/a | -11.9x | 3.2x |
| Thu, 18 Dec 2025 | zł1.4b | zł464.6m | -zł124,641,157.00 | n/a | -11.2x | 3x |
| Sat, 15 Nov 2025 | zł1.4b | zł507.6m | -zł114,663,001.00 | 1630.3x | -12.3x | 2.8x |
| Mon, 13 Oct 2025 | zł1.4b | zł507.6m | -zł114,663,001.00 | 1425x | -11.9x | 2.7x |
| Wed, 10 Sep 2025 | zł1.4b | zł460.9m | -zł129,094,851.00 | 37.8x | -11.2x | 3.1x |
| Fri, 08 Aug 2025 | zł1.5b | zł461.1m | -zł128,888,382.00 | 39x | -11.8x | 3.3x |
| Sun, 06 Jul 2025 | zł1.4b | zł461.1m | -zł128,888,382.00 | 33.1x | -11.2x | 3.1x |
| Tue, 03 Jun 2025 | zł1.4b | zł457.8m | -zł130,948,382.00 | n/a | -10.7x | 3.1x |
| Thu, 01 May 2025 | zł1.6b | zł452.3m | -zł123,092,243.00 | 49.3x | -12.8x | 3.5x |
| Sat, 29 Mar 2025 | zł1.6b | zł452.3m | -zł123,092,243.00 | 49.3x | -13x | 3.5x |
| Mon, 24 Feb 2025 | zł1.7b | zł427.2m | -zł63,400,243.00 | 16.9x | -27.4x | 4.1x |
| Wed, 22 Jan 2025 | zł1.7b | zł427.0m | -zł65,964,174.00 | 15.6x | -26.2x | 4x |
| Fri, 20 Dec 2024 | zł1.9b | zł427.0m | -zł65,964,174.00 | 16.8x | -29.4x | 4.5x |
| Sun, 17 Nov 2024 | zł2.2b | zł421.9m | -zł72,811,689.00 | 19.9x | -30.3x | 5.2x |
| Tue, 15 Oct 2024 | zł2.5b | zł413.2m | -zł64,500,689.00 | 23.5x | -38.4x | 6x |
| Thu, 12 Sep 2024 | zł2.5b | zł413.4m | -zł37,576,869.00 | 17.7x | -65.3x | 5.9x |
| Sat, 10 Aug 2024 | zł2.4b | zł413.5m | -zł32,092,283.00 | 17.8x | -75.3x | 5.8x |
| Mon, 08 Jul 2024 | zł2.4b | zł413.5m | -zł32,092,283.00 | 19.1x | -75.9x | 5.9x |
| Wed, 05 Jun 2024 | zł2.5b | zł413.5m | -zł32,092,283.00 | 17.8x | -77.9x | 6x |
| Fri, 03 May 2024 | zł2.5b | zł421.0m | -zł26,364,957.00 | 18.5x | -94.5x | 5.9x |
| Sun, 31 Mar 2024 | zł2.6b | zł421.0m | -zł26,364,957.00 | 17.5x | -97.7x | 6.1x |
| Tue, 27 Feb 2024 | zł2.5b | zł495.9m | -zł52,637,957.00 | 44.4x | -47.9x | 5.1x |
| Thu, 25 Jan 2024 | zł2.5b | zł495.2m | -zł50,454,191.00 | 44.7x | -48.6x | 5x |
| Sat, 23 Dec 2023 | zł2.6b | zł495.2m | -zł50,454,191.00 | 45.6x | -51.4x | 5.2x |
| Mon, 20 Nov 2023 | zł2.5b | zł509.3m | -zł33,328,342.00 | 31.6x | -74.8x | 4.9x |
| Wed, 18 Oct 2023 | zł2.9b | zł512.0m | -zł37,354,934.00 | 33.5x | -76.5x | 5.6x |
| Fri, 15 Sep 2023 | zł2.8b | zł507.5m | -zł51,266,934.00 | 41.7x | -53.7x | 5.4x |
| Sun, 13 Aug 2023 | zł2.9b | zł512.4m | -zł61,559,268.00 | 47.8x | -46.9x | 5.6x |
Price to Earnings Ratio
-46.9x
Current Industry PE
- Investors are pessimistic on the Polish Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 4.2x is higher than the industry's current PS ratio of 2.2x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Revenues have also declined 4.4% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Comparison
How does Polish Clinical Research and Equipment compare with similar industries?
| PL Market | 4.33% | |
| Healthcare | 1.48% | |
| Life Sciences | 4.36% | |
| Clinical Research and Equipment | 4.36% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| SLV Selvita | zł28.00 | 5.3% +zł25.7m | -17.2% | PS1.4x | |
| RVU Ryvu Therapeutics | zł16.02 | 6.8% +zł23.6m | -47.3% | PS4.2x |